Figure - available from: Open Life Sciences
This content is subject to copyright. Terms and conditions apply.
HLA-G 14 bp ins/del polymorphism and pre-transplantation sHLA-G levels in kidney transplant recipients. sHLA-G values were expressed as mean±SD. P values were calculated using unpaired Student’s t test with Welch correction. * P value of <0.05 was considered as statistically significant. +14 – HLA-G 14 bp insertion in exon 8, −14 – HLA-G 14 bp deletion in exon 8, N – number
Source publication
Human leukocyte antigen G (HLA-G) is a non-classical HLA class I protein with various immunosuppressive functions. Besides its profound effect to induce fetal tolerance, HLA-G has been also found to enhance graft acceptance. The aim of the study was to analyse the association between HLA-G 14 bp insertion/deletion polymorphism, soluble HLA-G level...
Similar publications
HLA-G es una molécula clase I no clásica (Ib) del Complejo Mayor de Histocompatibilidad Humano (CMH), adopta siete isoformas, resultado del empalme alternativo de un mismo RNA inmaduro, cuatro se encuentran ligadas a la membrana (HLA-G1,-G2, -G3, -G4) y las otras tres formas son solubles (HLA-G5, - G6, -G7), teniendo en común el dominio extracelula...
Objectives:
To identify possible association between the selected HLA-G gene polymorphisms and risk of pre-eclampsia.
Background:
Pre-eclampsia is a serious multisystem disorder that affects women during pregnancy. Despite many research studies, the pathology of pre-eclampsia is not fully understood. Human leukocyte antigen G (HLA-G) belongs to...
Citations
HLA-G is a non-classical class I HLA molecule that induces tolerance by acting on receptors of both innate and adaptive immune cells. When overexpressed in tumors, limits surveillance by the immune system. The HLA-G gene shows several polymorphisms involved in mRNA and protein levels. We decided to study the implication of two polymorphisms (rs371194629; 14bp INS/DEL and rs1063320; +3142 C/G) in paired tissue samples (tumoral and non-tumoral) from 107 Spanish patients with gastric adenocarcinoma and 58 healthy control individuals, to assess the possible association of the HLA-G gene with gastric adenocarcinoma susceptibility, disease progression and survival. The presence of somatic mutations involving these polymorphisms was also analyzed. The frequency of the 14bp DEL allele was increased in patients (70.0%) compared to controls (57.0%, p=0.025). In addition, the haplotype formed by the combination of the 14bp DEL/+3142 C variants is also increased in patients (54.1% vs 44.4%, p=0.034, OR=1.74 CI95% 1.05-2.89). Kaplan-Meier analysis revealed that 14bp DEL/DEL patients showed lower 5-year life-expectancy than INS/DEL or INS/INS (p=0.041). Adjusting for TNM staging (Cox regression analysis) disclosed a significant difference in death risk (p=0.03) with an expected hazard 2.6 times higher. Finally, no somatic mutations were found when comparing these polymorphisms in tumoral vs non-tumoral tissues, which indicates that this is a preexisting condition in patients and not a de novo, tumor-restricted, event. In conclusion, the variants predominant in patients were those increasing HLA-G mRNA stability and HLA-G expression, clearly involving this molecule in gastric adenocarcinoma susceptibility, disease progression and survival and making it a potential target for immunotherapeutic approaches.
The aim of this study was to evaluate the relation of Human Leukocyte Antigen-G (HLA-G) 14 bp ins/del (insertion/deletion) polymorphism and soluble HLA-G (sHLA-G) level with rejection in kidney transplant recipients.
The study was planned as a case-control study involving two hundred fifty kidney transplant recipients. The case group consisted of 125 (female/male:56/69) kidney transplant recipients diagnosed with acute (n=52) and chronic rejection (n=73). The control group consisted of one hundred twenty-five kidney transplant patients with no acute or chronic rejection matched by gender and age in the case group. The sHLA-G level in the recipient's plasma (at the time of rejection for the case, the same time as the case after the transplant for control) was analyzed by Enzyme-Linked Immunosorbent Assay (ELISA). HLA-G 3' untranslated region (3’UTR) polymorphism of recipient and donor was determined using agarose gel electrophoresis and DNA sequencing method.
In our study, it was shown that acute rejection rate increased 1.06 times and chronic rejection rate increased 1.14 times in kidney transplant recipients with low serum sHLA-G levels. The rejection patients with the HLA-G 14 bp del/del genotype had higher sHLA-G levels post-transplantation. The frequency of acute rejection was lower in patients with HLA- G 14 bp del/del polymorphism than those with ins/ins and ins/del polymorphisms.
This study proposes that HLA-G 3'UTR polymorphism and sHLA-G level might be useful in prediction of rejection in kidney transplant recipients.
Background: Human leukocyte antigen G (HLA-G) belongs to non-classical MHC class I molecules that is involved in the suppression of immune response. As HLA-G plays important role in the maintenance of fetal tolerance, its overexpression has been associated with tumor progression. For the regulation of HLA-G levels, genetic variants within the 5′ upstream regulatory region (5′URR) are of crucial importance. Our study aimed to analyze the association between 16 HLA-G 5′URR variants, sHLA-G level and clinical variables in glioma patients.
Methods: We investigated 59 patients with gliomas (mean age 54.70 ± 15.10 years) and 131 healthy controls (mean age 41.45 ± 9.75 years). Patient’s blood was obtained on the day of surgical treatment. The HLA-G 5′URR polymorphisms were typed by direct sequencing and the plasma level of sHLA-G assessed by ELISA.
Results: Haploblock within HLA-G 5′URR consisting of −762 T, −716 G, −689 G, −666 T, −633 A, followed by −486 C and −201 A alleles were significantly more frequent in patients with gliomas than in the controls (p < 0.05). No correlation of HLA-G 5′URR variants with sHLA-G plasma level was found. Analysis of HLA-G 5′URR variants with main clinical variables in patients with grade IV gliomas revealed that haploblock carriers of -762CT, -716TG, -689AG, - 666GT, -633GA, -486AC, -477GC, -201GA followed by -369AC carriers tend to have lower age at onset as compared to other genotype carriers (p = 0.04).
Conclusion: Our results suggest genetic association of HLA-G 5′URR variants with risk of developing gliomas and possible contribution of HLA-G to disease pathology.
Background: Human leukocyte antigen G (HLA-G) belongs to nonclassical HLA I molecule involving in the suppression of immune response. Besides its profound effect to induce fetal tolerance, HLA-G expression has been associated with allograft acceptance. For the regulation of HLA-G levels, polymorphic sites within the 3′ untranslated region (3′UTR) are of crucial importance. The aim of the study was to analyze the association between several HLA-G 3′UTR variants (+3003T/C, +3010C/G, +3027C/A, +3035C/T, +3142G/C, +3187A/G, and +3196C/G), soluble HLA-G (sHLA-G) level, and kidney graft outcome in the Slovak Caucasian population.
Methods: We investigated 69 kidney transplant recipients (45 males, 24 females) of age 27–65 years. Out of this group, 37 recipients developed acute rejection that was biopsy proven. Recipient’s plasma was obtained at 1 day before transplantation and analyzed by ELISA. The HLA-G 3′UTR polymorphisms were typed by direct sequencing.
Results: In the recipients with stable allograft function, significantly higher values of sHLA-G were found in the homozygous +3010GG, +3142CC, +3187GG, and +3196CC carriers in comparison to the acute rejection recipients (P = 0.01-0.05).
Conclusion: The study demonstrated genetic association between HLA-G 3′UTR variants and sHLA-G level in kidney recipients leading to graft acceptance. We suggest to monitor the pretransplantation sHLA-G level as additional marker to predict kidney graft outcome. Abbreviations: AMR: Antibody-mediated rejection; APC: antigen-presenting cell; CD: cluster of designation; del: deletion; HLA: human leukocyte antigen; ILT: immunoglobulin-like transcript; ins: insertion; KIR: killer-cell immunoglobulin-like receptor; NK: natural killer; sHLA-G: soluble HLA-G; SNP: single nucleotide polymorphism; TCMR: T cell-mediated rejection; URR: upstream regulatory region; UTR: untranslated region
